ResearcherHangzhou Medical CollegeActive in the last 2 years
Wenhui Ouyang
Matched on ORCID iD 0009-0004-2185-4846; OpenAlex author ID A5147319136. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2026: 3 papers
Papers 3
- Dynamic Alterations of Site-Specific N-Glycoform and Plasma Proteasome Signatures Stratify Chemotherapy Benefit in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.mcpro.2026.101642↗
- Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.trsl.2026.09.009↗
- Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma. First author DOI 10.4143/crt.2025.510↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Shanying Gui · 3 shared papers, 2026 · strength 0.92
- Paper Therapeutic Co-targeting of oxidative phosphorylation and pyrimidine synthesis restores gemcitabine response in pancrea… DOI 10.1016/j.trsl.2026.09.009↗
- Paper Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2025.510↗
- Paper Dynamic Alterations of Site-Specific N-Glycoform and Plasma Proteasome Signatures Stratify Chemotherapy Benefit in Panc… DOI 10.1016/j.mcpro.2026.101642↗
- Hezhi Fang · 2 shared papers, 2026 · strength 0.59
- Paper Extracellular Vesicle-Derived Adenosine as a Diagnostic Metabolic Biomarker for Pancreatic Ductal Adenocarcinoma. DOI 10.4143/crt.2025.510↗
- Paper Dynamic Alterations of Site-Specific N-Glycoform and Plasma Proteasome Signatures Stratify Chemotherapy Benefit in Panc… DOI 10.1016/j.mcpro.2026.101642↗
- Tao Xia · 1 shared paper, 2026 · strength 0.32
- Yiping Mou · 1 shared paper, 2026 · strength 0.32
- Jianxin Lyu · 1 shared paper, 2026 · strength 0.27
- Wei Cui · 1 shared paper, 2026 · strength 0.27
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.